K-Ras-IN-4, identified by its CAS number 3044773-77-2, is a small molecule inhibitor specifically targeting the K-Ras protein, which is a key player in various signaling pathways related to cell growth and proliferation. This compound is particularly significant in cancer research, as mutations in the K-Ras gene are commonly associated with several types of cancers, including pancreatic, colorectal, and lung cancers. K-Ras-IN-4 functions by binding to the K-Ras protein, thereby inhibiting its activity and disrupting downstream signaling pathways that promote tumor growth. The compound is characterized by its selective inhibition, which aims to minimize effects on non-mutated Ras proteins and reduce potential side effects. Additionally, K-Ras-IN-4 has been studied for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), which are crucial for its development as a therapeutic agent. Ongoing research continues to explore its efficacy and safety in clinical settings, highlighting its potential as a targeted cancer therapy.

K-Ras-IN-4

3044773-77-2: K-Ras-IN-4, identified by its CAS number 3044773-77-2, is a small molecule inhibitor specifically targeting the K-Ras protein, which is a key player in various signaling pathways related to cell growth and proliferation. This compound is particularly significant in cancer research, as mutations in the K-Ras gene are commonly associated with several types of cancers, including pancreatic, colorectal, and lung cancers. K-Ras-IN-4 functions by binding to the K-Ras protein, thereby inhibiting its activity and disrupting downstream signaling pathways that promote tumor growth. The compound is characterized by its selective inhibition, which aims to minimize effects on non-mutated Ras proteins and reduce potential side effects. Additionally, K-Ras-IN-4 has been studied for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), which are crucial for its development as a therapeutic agent. Ongoing research continues to explore its efficacy and safety in clinical settings, highlighting its potential as a targeted cancer therapy.

<p>K-Ras-IN-4 (compound CP163) is an inhibitor of K-Ras.</p>

CAS 3044773-77-2

K-Ras-IN-4

K-Ras-IN-4

Ref: TM-T200471